Research programme: antibacterials - Basilea Pharmaceutica
Alternative Names: BAL 19764; BAL 29880; BAL0019764; BAL0029641; BAL0030205; BAL2057; BAL30376; HKI9924109Latest Information Update: 04 Nov 2017
At a glance
- Originator Basilea Pharmaceutica
- Class Macrolides; Monobactams
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acne; Gram-negative infections; Gram-positive infections; Rosacea
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acne in Switzerland (Topical)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in Germany (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gram-negative-infections in Switzerland (Parenteral)